WO2008004100A3 - Composés thérapeutiques - Google Patents

Composés thérapeutiques Download PDF

Info

Publication number
WO2008004100A3
WO2008004100A3 PCT/IB2007/001887 IB2007001887W WO2008004100A3 WO 2008004100 A3 WO2008004100 A3 WO 2008004100A3 IB 2007001887 W IB2007001887 W IB 2007001887W WO 2008004100 A3 WO2008004100 A3 WO 2008004100A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic compounds
methods
solvates
formula
preparation
Prior art date
Application number
PCT/IB2007/001887
Other languages
English (en)
Other versions
WO2008004100A9 (fr
WO2008004100A2 (fr
Inventor
Simon Paul Planken
Scott Channing Sutton
Tin Hung Tran
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of WO2008004100A2 publication Critical patent/WO2008004100A2/fr
Publication of WO2008004100A3 publication Critical patent/WO2008004100A3/fr
Publication of WO2008004100A9 publication Critical patent/WO2008004100A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I), ou leurs sels ou solvates de qualité pharmaceutique, leurs méthodes de synthèse, leurs méthodes d'application et les formules pharmaceutiques les incluant.
PCT/IB2007/001887 2006-07-05 2007-06-25 Composés thérapeutiques WO2008004100A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60/706,597 2005-08-09
US70659706P 2006-07-05 2006-07-05
US91519907P 2007-05-01 2007-05-01
US60/915,199 2007-05-01

Publications (3)

Publication Number Publication Date
WO2008004100A2 WO2008004100A2 (fr) 2008-01-10
WO2008004100A3 true WO2008004100A3 (fr) 2011-06-16
WO2008004100A9 WO2008004100A9 (fr) 2012-04-19

Family

ID=38894942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/001887 WO2008004100A2 (fr) 2006-07-05 2007-06-25 Composés thérapeutiques

Country Status (1)

Country Link
WO (1) WO2008004100A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
CN102083817A (zh) * 2008-04-04 2011-06-01 Irm责任有限公司 作为itpkb抑制剂的化合物和组合物
WO2010057118A2 (fr) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
CN102971314B (zh) 2010-04-28 2016-03-23 拜耳知识产权有限责任公司 酮基杂芳基哌啶和酮基杂芳基哌嗪衍生物作为杀菌剂
JP6986955B2 (ja) * 2016-12-28 2021-12-22 キッセイ薬品工業株式会社 ピラゾール誘導体の製造方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1133385B (de) * 1960-04-14 1962-07-19 Zyma Blaes A G Chem Fab Verfahren zur Herstellung von 3-Pyrazyl-pyrazolderivaten
WO2005066162A1 (fr) * 2003-12-23 2005-07-21 Human Biomolecular Research Institute Composes synthetiques et derives de ceux-ci en tant que modulateurs de fumee ou d'ingestion de nicotine et du cancer du poumon
WO2005095350A1 (fr) * 2004-03-23 2005-10-13 Amgen Inc. Composes de pyrazole et utilisations
US20060009645A1 (en) * 2004-07-12 2006-01-12 Vanessa Smith Naphthylene derivatives as cytochrome P450 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003171381A (ja) 2001-09-25 2003-06-20 Takeda Chem Ind Ltd エントリー阻害剤
JP2003119137A (ja) 2001-10-10 2003-04-23 Japan Tobacco Inc Ｈｉｖ阻害剤
CA2463975A1 (fr) 2001-10-26 2003-05-01 Maria Emilia Di Francesco Inhibiteurs de l'integrase du vih a base de dihydroxypyrimidine carboxamide
JP4497347B2 (ja) 2001-12-05 2010-07-07 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する誘導体
RU2284315C2 (ru) 2001-12-12 2006-09-27 Бристол-Маерс Сквибб Компани Ингибиторы вич-интегразы и содержащие их фармацевтические композиции
ATE516029T1 (de) 2001-12-21 2011-07-15 Tibotec Pharm Ltd Sulfonamide die ein heterozyklus-substituiertes phenyl enthalten als broadspectrum-hiv-protease- inhibitoren
CA2472372C (fr) 2002-01-17 2010-08-17 Melissa Egbertson Carboxamides hydroxynaphthyridinone utiles comme inhibiteurs de l'integrase du vih
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
JP2006511554A (ja) 2002-12-13 2006-04-06 スミスクライン ビーチャム コーポレーション Ｃｃｒ５アンタゴニストとしてのピペリジン誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1133385B (de) * 1960-04-14 1962-07-19 Zyma Blaes A G Chem Fab Verfahren zur Herstellung von 3-Pyrazyl-pyrazolderivaten
WO2005066162A1 (fr) * 2003-12-23 2005-07-21 Human Biomolecular Research Institute Composes synthetiques et derives de ceux-ci en tant que modulateurs de fumee ou d'ingestion de nicotine et du cancer du poumon
WO2005095350A1 (fr) * 2004-03-23 2005-10-13 Amgen Inc. Composes de pyrazole et utilisations
US20060009645A1 (en) * 2004-07-12 2006-01-12 Vanessa Smith Naphthylene derivatives as cytochrome P450 inhibitors

Also Published As

Publication number Publication date
WO2008004100A9 (fr) 2012-04-19
WO2008004100A2 (fr) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2007087548A3 (fr) Composés chimiques
IL260127B (en) mek inhibitors and methods of using them
WO2007027527A3 (fr) Composes d'isoindole-imide et compositions renfermant ceux-ci et procedes d'utilisation de ceux-ci
WO2007034312A3 (fr) Composes therapeutiques
MX2009000482A (es) Compuestos terapeuticos.
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2006096444A3 (fr) Composes chimiques
WO2008115516A3 (fr) Dérivés d'isoindoline 4'-o-substitués, compositions renfermant ces dérivés et procédés d'utilisation associés
WO2006011050A3 (fr) Derives de pyridine
WO2008027542A3 (fr) Composés d'isoindoline substituée en 5
TW200613243A (en) Novel compounds
WO2006025070A3 (fr) Nebivolol et ses sels pharmaceutiquement acceptables, procede de preparation et compositions pharmaceutiques de nebivolol
WO2009024611A3 (fr) 4-benzylaminoquinoléines, compositions pharmaceutiques les contenant, et leur utilisation en thérapie
WO2006082523A3 (fr) Compositions pharmaceutiques de metformine
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
TW200626553A (en) Novel compounds
TW200639156A (en) New compounds
WO2007095039A3 (fr) Formulations pharmaceutiques
WO2009140341A3 (fr) Compositions d'atorvastatine
WO2008008660A3 (fr) Composés thérapeutiques
WO2004105773A3 (fr) Utilisation de s1p
WO2008004100A9 (fr) Composés thérapeutiques
WO2008039894A3 (fr) Compositions pharmaceutiques d'atorvastatine
WO2005070903A3 (fr) Composes

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07734957

Country of ref document: EP

Kind code of ref document: A2